周一晚间,生物制药公司拜玛林制药(BioMarin Pharmaceutical Inc,股票代码:BMRN)股价在夜盘交易中大涨7.69%,引发投资者广泛关注。这一显著涨幅主要源于公司发布的2025年第二季度财报远超市场预期。
根据公司公布的财报,拜玛林制药第二季度调整后每股收益达1.23美元,远高于分析师平均预期的0.83美元。公司营收同比增长15.9%,达到8.2541亿美元,同样超过了分析师预期的7.5998亿美元。其中,Voxogo产品收入同比增长20%,酶疗法收入同比增长15%,显示出公司核心业务的强劲增长势头。
除了亮眼的财务业绩外,拜玛林制药管理层还上调了2025年全年收入、非GAAP运营利润率和每股收益的指导。公司展望未来,表示2025年下半年将继续保持强劲增长,并计划在2026年启动BMN 333的剂量发现阶段2/3试验。此外,公司近期完成了Innozyme的收购,进一步多元化其酶疗法产品组合,为长期发展奠定基础。这些积极因素共同推动了投资者信心,促使股价在财报发布后大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.